Outcome with the hyper-CVAD regimens in lymphoblastic lymphoma

Deborah A. Thomas, Susan O'Brien, Jorge Cortes, Francis J. Giles, Stefan Faderl, Srdan Verstovsek, Alessandra Ferrajoli, Charles Koller, Miloslav Beran, Sherry Pierce, Chul S. Ha, Fernando Cabanillas, Michael J. Keating, Hagop Kantarjian

Research output: Contribution to journalArticle

Abstract

Therapy of lymphoblastic lymphoma (LL) has evolved with use of chemotherapy regimens modeled after those for acute lymphocytic leukemia (ALL). We treated 33 patients with LL with the intensive chemotherapy regimens hyper-CVAD (fractionated cyclophosphamide, vincristine, Adriamycin, and dexamethasone) or modified hyper-CVAD used for ALL at our institution. Induction consolidation was administered with 8 or 9 alternating cycles of chemotherapy over 5 to 6 months with intrathecal chemotherapy prophylaxis, followed by maintenance therapy. Consolidative radiation therapy was given to patients with mediastinal disease at presentation. No consolidation with autologous or allogeneic stem cell transplantation was performed. At diagnosis, 80% were T-cell immunophenotype, 70% were stages III to IV, 70% had mediastinal involvement, and 9% had central nervous system (CNS) disease. Of the patients, 30 (91%) achieved complete remission, and 3 (9%) achieved partial response. Within a median of 13 months, 10 patients (30%) relapsed or progressed. Estimates for 3-year progression-free and overall survival for the 33 patients were 66% and 70%, respectively. Estimates for the patients with known T-cell immunophenotype were 62% and 67%, respectively. No parameters (eg, age, stage, serum lactate dehydrogenase [LDH], β2 microglobulin) appeared to influence outcome except for CNS disease at presentation. Modification of the hyper-CVAD regimen with anthracycline intensification did not improve outcome. Other modifications of the program could include incorporation of monoclonal antibodies and/or nucleoside analogs, particularly for slow responders or those with residual mediastinal disease.

Original languageEnglish (US)
Pages (from-to)1624-1630
Number of pages7
JournalBlood
Volume104
Issue number6
DOIs
StatePublished - Sep 15 2004
Externally publishedYes

Fingerprint

Chemotherapy
Precursor Cell Lymphoblastic Leukemia-Lymphoma
T-cells
Neurology
Mediastinal Diseases
Consolidation
Drug Therapy
Central Nervous System Diseases
Anthracyclines
Radiotherapy
Vincristine
Stem cells
Nucleosides
Doxorubicin
Cyclophosphamide
Dexamethasone
T-Lymphocytes
Monoclonal Antibodies
Stem Cell Transplantation
Disease-Free Survival

ASJC Scopus subject areas

  • Biochemistry
  • Immunology
  • Hematology
  • Cell Biology

Cite this

Thomas, D. A., O'Brien, S., Cortes, J., Giles, F. J., Faderl, S., Verstovsek, S., ... Kantarjian, H. (2004). Outcome with the hyper-CVAD regimens in lymphoblastic lymphoma. Blood, 104(6), 1624-1630. https://doi.org/10.1182/blood-2003-12-4428

Outcome with the hyper-CVAD regimens in lymphoblastic lymphoma. / Thomas, Deborah A.; O'Brien, Susan; Cortes, Jorge; Giles, Francis J.; Faderl, Stefan; Verstovsek, Srdan; Ferrajoli, Alessandra; Koller, Charles; Beran, Miloslav; Pierce, Sherry; Ha, Chul S.; Cabanillas, Fernando; Keating, Michael J.; Kantarjian, Hagop.

In: Blood, Vol. 104, No. 6, 15.09.2004, p. 1624-1630.

Research output: Contribution to journalArticle

Thomas, DA, O'Brien, S, Cortes, J, Giles, FJ, Faderl, S, Verstovsek, S, Ferrajoli, A, Koller, C, Beran, M, Pierce, S, Ha, CS, Cabanillas, F, Keating, MJ & Kantarjian, H 2004, 'Outcome with the hyper-CVAD regimens in lymphoblastic lymphoma', Blood, vol. 104, no. 6, pp. 1624-1630. https://doi.org/10.1182/blood-2003-12-4428
Thomas DA, O'Brien S, Cortes J, Giles FJ, Faderl S, Verstovsek S et al. Outcome with the hyper-CVAD regimens in lymphoblastic lymphoma. Blood. 2004 Sep 15;104(6):1624-1630. https://doi.org/10.1182/blood-2003-12-4428
Thomas, Deborah A. ; O'Brien, Susan ; Cortes, Jorge ; Giles, Francis J. ; Faderl, Stefan ; Verstovsek, Srdan ; Ferrajoli, Alessandra ; Koller, Charles ; Beran, Miloslav ; Pierce, Sherry ; Ha, Chul S. ; Cabanillas, Fernando ; Keating, Michael J. ; Kantarjian, Hagop. / Outcome with the hyper-CVAD regimens in lymphoblastic lymphoma. In: Blood. 2004 ; Vol. 104, No. 6. pp. 1624-1630.
@article{c13bddbf794342b7b08b5cae6dee782f,
title = "Outcome with the hyper-CVAD regimens in lymphoblastic lymphoma",
abstract = "Therapy of lymphoblastic lymphoma (LL) has evolved with use of chemotherapy regimens modeled after those for acute lymphocytic leukemia (ALL). We treated 33 patients with LL with the intensive chemotherapy regimens hyper-CVAD (fractionated cyclophosphamide, vincristine, Adriamycin, and dexamethasone) or modified hyper-CVAD used for ALL at our institution. Induction consolidation was administered with 8 or 9 alternating cycles of chemotherapy over 5 to 6 months with intrathecal chemotherapy prophylaxis, followed by maintenance therapy. Consolidative radiation therapy was given to patients with mediastinal disease at presentation. No consolidation with autologous or allogeneic stem cell transplantation was performed. At diagnosis, 80{\%} were T-cell immunophenotype, 70{\%} were stages III to IV, 70{\%} had mediastinal involvement, and 9{\%} had central nervous system (CNS) disease. Of the patients, 30 (91{\%}) achieved complete remission, and 3 (9{\%}) achieved partial response. Within a median of 13 months, 10 patients (30{\%}) relapsed or progressed. Estimates for 3-year progression-free and overall survival for the 33 patients were 66{\%} and 70{\%}, respectively. Estimates for the patients with known T-cell immunophenotype were 62{\%} and 67{\%}, respectively. No parameters (eg, age, stage, serum lactate dehydrogenase [LDH], β2 microglobulin) appeared to influence outcome except for CNS disease at presentation. Modification of the hyper-CVAD regimen with anthracycline intensification did not improve outcome. Other modifications of the program could include incorporation of monoclonal antibodies and/or nucleoside analogs, particularly for slow responders or those with residual mediastinal disease.",
author = "Thomas, {Deborah A.} and Susan O'Brien and Jorge Cortes and Giles, {Francis J.} and Stefan Faderl and Srdan Verstovsek and Alessandra Ferrajoli and Charles Koller and Miloslav Beran and Sherry Pierce and Ha, {Chul S.} and Fernando Cabanillas and Keating, {Michael J.} and Hagop Kantarjian",
year = "2004",
month = "9",
day = "15",
doi = "10.1182/blood-2003-12-4428",
language = "English (US)",
volume = "104",
pages = "1624--1630",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "6",

}

TY - JOUR

T1 - Outcome with the hyper-CVAD regimens in lymphoblastic lymphoma

AU - Thomas, Deborah A.

AU - O'Brien, Susan

AU - Cortes, Jorge

AU - Giles, Francis J.

AU - Faderl, Stefan

AU - Verstovsek, Srdan

AU - Ferrajoli, Alessandra

AU - Koller, Charles

AU - Beran, Miloslav

AU - Pierce, Sherry

AU - Ha, Chul S.

AU - Cabanillas, Fernando

AU - Keating, Michael J.

AU - Kantarjian, Hagop

PY - 2004/9/15

Y1 - 2004/9/15

N2 - Therapy of lymphoblastic lymphoma (LL) has evolved with use of chemotherapy regimens modeled after those for acute lymphocytic leukemia (ALL). We treated 33 patients with LL with the intensive chemotherapy regimens hyper-CVAD (fractionated cyclophosphamide, vincristine, Adriamycin, and dexamethasone) or modified hyper-CVAD used for ALL at our institution. Induction consolidation was administered with 8 or 9 alternating cycles of chemotherapy over 5 to 6 months with intrathecal chemotherapy prophylaxis, followed by maintenance therapy. Consolidative radiation therapy was given to patients with mediastinal disease at presentation. No consolidation with autologous or allogeneic stem cell transplantation was performed. At diagnosis, 80% were T-cell immunophenotype, 70% were stages III to IV, 70% had mediastinal involvement, and 9% had central nervous system (CNS) disease. Of the patients, 30 (91%) achieved complete remission, and 3 (9%) achieved partial response. Within a median of 13 months, 10 patients (30%) relapsed or progressed. Estimates for 3-year progression-free and overall survival for the 33 patients were 66% and 70%, respectively. Estimates for the patients with known T-cell immunophenotype were 62% and 67%, respectively. No parameters (eg, age, stage, serum lactate dehydrogenase [LDH], β2 microglobulin) appeared to influence outcome except for CNS disease at presentation. Modification of the hyper-CVAD regimen with anthracycline intensification did not improve outcome. Other modifications of the program could include incorporation of monoclonal antibodies and/or nucleoside analogs, particularly for slow responders or those with residual mediastinal disease.

AB - Therapy of lymphoblastic lymphoma (LL) has evolved with use of chemotherapy regimens modeled after those for acute lymphocytic leukemia (ALL). We treated 33 patients with LL with the intensive chemotherapy regimens hyper-CVAD (fractionated cyclophosphamide, vincristine, Adriamycin, and dexamethasone) or modified hyper-CVAD used for ALL at our institution. Induction consolidation was administered with 8 or 9 alternating cycles of chemotherapy over 5 to 6 months with intrathecal chemotherapy prophylaxis, followed by maintenance therapy. Consolidative radiation therapy was given to patients with mediastinal disease at presentation. No consolidation with autologous or allogeneic stem cell transplantation was performed. At diagnosis, 80% were T-cell immunophenotype, 70% were stages III to IV, 70% had mediastinal involvement, and 9% had central nervous system (CNS) disease. Of the patients, 30 (91%) achieved complete remission, and 3 (9%) achieved partial response. Within a median of 13 months, 10 patients (30%) relapsed or progressed. Estimates for 3-year progression-free and overall survival for the 33 patients were 66% and 70%, respectively. Estimates for the patients with known T-cell immunophenotype were 62% and 67%, respectively. No parameters (eg, age, stage, serum lactate dehydrogenase [LDH], β2 microglobulin) appeared to influence outcome except for CNS disease at presentation. Modification of the hyper-CVAD regimen with anthracycline intensification did not improve outcome. Other modifications of the program could include incorporation of monoclonal antibodies and/or nucleoside analogs, particularly for slow responders or those with residual mediastinal disease.

UR - http://www.scopus.com/inward/record.url?scp=4444268220&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=4444268220&partnerID=8YFLogxK

U2 - 10.1182/blood-2003-12-4428

DO - 10.1182/blood-2003-12-4428

M3 - Article

C2 - 15178574

AN - SCOPUS:4444268220

VL - 104

SP - 1624

EP - 1630

JO - Blood

JF - Blood

SN - 0006-4971

IS - 6

ER -